Hydrogel Dressings for Chronic Wound Healing in Diabetes: Beyond Hydration.

Journal of pharmaceutics & drug delivery research Pub Date : 2021-01-01 Epub Date: 2020-12-21
Paul R Hartmeier, Ngoc B Pham, Ketki Y Velankar, Fadi Issa, Nick Giannoukakis, Wilson S Meng
{"title":"Hydrogel Dressings for Chronic Wound Healing in Diabetes: Beyond Hydration.","authors":"Paul R Hartmeier, Ngoc B Pham, Ketki Y Velankar, Fadi Issa, Nick Giannoukakis, Wilson S Meng","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic wounds caused by diabetes are a significant medical challenge. Complications from non-healing can result in dire consequences for patients and cost the healthcare system billions of dollars annually. Non-healing in wounds for diabetic patient's results from a combination of factors which impair clearing of injured tissue, proliferation of healthy cell populations and increase risk of infection. Wound dressings continue to form the basis for the treatment of chronic wounds. Traditionally, these focused solely on hydration of the wound site and mitigating infection risk. Hydrogel systems are ready made to meet these basic requirements due to their intrinsic hydration properties and ability to deliver active ingredients. Flexibility in materials and methods of release allowed these systems to remain targets of research into the 21st century. Improved understanding of the wound environment and healing cascades has led to the development of more advanced systems which incorporate endogenous growth factors and living cells. Despite their promise, clinical efficacy of these systems has remained a challenge. Further, the regulatory pathways for approval add a layer of complexity to translate pre-clinical work into marketed products. In this review, we discuss systems currently in clinical use, pre-clinical directions and regulatory challenges for hydrogels in the treatment of diabetic chronic wounds.</p>","PeriodicalId":87311,"journal":{"name":"Journal of pharmaceutics & drug delivery research","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473423/pdf/nihms-1834059.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutics & drug delivery research","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/12/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic wounds caused by diabetes are a significant medical challenge. Complications from non-healing can result in dire consequences for patients and cost the healthcare system billions of dollars annually. Non-healing in wounds for diabetic patient's results from a combination of factors which impair clearing of injured tissue, proliferation of healthy cell populations and increase risk of infection. Wound dressings continue to form the basis for the treatment of chronic wounds. Traditionally, these focused solely on hydration of the wound site and mitigating infection risk. Hydrogel systems are ready made to meet these basic requirements due to their intrinsic hydration properties and ability to deliver active ingredients. Flexibility in materials and methods of release allowed these systems to remain targets of research into the 21st century. Improved understanding of the wound environment and healing cascades has led to the development of more advanced systems which incorporate endogenous growth factors and living cells. Despite their promise, clinical efficacy of these systems has remained a challenge. Further, the regulatory pathways for approval add a layer of complexity to translate pre-clinical work into marketed products. In this review, we discuss systems currently in clinical use, pre-clinical directions and regulatory challenges for hydrogels in the treatment of diabetic chronic wounds.

用于糖尿病慢性伤口愈合的水凝胶敷料:超越水合作用。
糖尿病引起的慢性伤口是一项重大的医疗挑战。伤口不愈合造成的并发症会给患者带来严重后果,并使医疗系统每年花费数十亿美元。糖尿病患者伤口不愈合是多种因素共同作用的结果,这些因素会影响损伤组织的清除、健康细胞群的增殖,并增加感染风险。伤口敷料仍然是治疗慢性伤口的基础。传统的伤口敷料只注重伤口部位的水合作用和降低感染风险。水凝胶系统因其固有的水合特性和输送活性成分的能力,可随时满足这些基本要求。材料和释放方法的灵活性使这些系统成为 21 世纪的研究目标。随着对伤口环境和愈合级联的进一步了解,人们开发出了结合内源性生长因子和活细胞的更先进系统。尽管这些系统前景广阔,但其临床疗效仍是一个挑战。此外,要将临床前研究成果转化为上市产品,审批监管途径也增加了复杂性。在本综述中,我们将讨论目前临床使用的系统、临床前研究方向以及水凝胶在治疗糖尿病慢性伤口方面所面临的监管挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信